NWHL Goaltender of the Year Lovisa Selander Returns for Second Season with the Boston Pride

by NWHL Media

FOR IMMEDIATE RELEASE MAY 20, 2020

 

BOSTON – NWHL Goaltender of the Year Lovisa Selander has signed a contract with the Boston Pride for the upcoming season.

In leading the 23-1 Pride to the regular season title, Selander was first in the league in wins (17), GAA (1.71) and save percentage (.941). Her save percentage set a single-season NWHL record among goaltenders starting at least six games. Selander ended her triumphant regular season with a 130:20 shutout streak – the longest by any goaltender in the 2019-20 season. In addition, Selander was named MVP of the 2020 NWHL All-Star Game in Boston.

“I could not be more excited to join the Boston Pride for another season,” said Selander, who was selected by Boston in the 2018 NWHL Draft. I’m incredibly thankful for the opportunity to play in Boston in front of our amazing fans.”

As her development as a goaltender continued in the pros with the Pride, Selander was selected for Team Sweden’s roster at the 4 Nations Tournament in December, 2019.

“I appreciate everyone who continues to support my life in hockey, including my family and friends, as well as the fans and everyone in the Boston Pride organization,” said Selander. “Being a member of the Pride has enabled me to improve every aspect of my game.”

Selander signed with Boston for her first pro season last summer. She is the NCAA all-time saves leader and, as a senior in 2018-19, was a Top Ten Finalist for the Patty Kazmaier Memorial Award. Selander was also honored that season as RPI’s MVP, the ECAC Goaltender of the Year, ECAC All-Academic, and she was RPI’s first-ever CCM/AHCA National All-America First Team selection.

Prior to attending RPI, the native of Sollentuna, Sweden played for SDE of the SDHL. She previously represented Sweden at the 2019 World Championships and 2018 4 Nations Tournament. In addition to playing professional hockey, Selander is a Process Development Engineer for Neurotech Pharmaceuticals, Inc.

Photo credit: Michelle Jay